Hikma agrees $50m settlement for Xyrem class actions.

Hikma Pharmaceuticals said on Thursday that it has entered into a preliminary $50m class settlement agreement that resolves the majority of its Xyrem (sodium oxybate) antitrust class action cases in the US.

Hikma Pharmaceuticals
08 May 2025 10:56:20

Source: Sharecast

The settlement relates o lawsuits brought against the company by third-party payors in the US who have purchased or been billed for Xyrem, a medication used to treat narcolepsy.

Sam Park, Hikma's General Counsel, said: "We are pleased to have reached a settlement agreement that protects the company's interests and provides clarity to our stakeholders.

"We are proud to have facilitated patients' access to a lower-cost authorised generic version of this essential medicine, years ahead of its patent expiration."

Hikma said that the settlement - which is subject to court approval - is not an admission of wrongdoing or liability, and that it will continue to defend itself "vigorously" against any litigation that this settlement does not resolve.

At 1040 BST, the shares were up 0.2% at 2,008p.

FTSE 100 ( UKX )

ISIN: N/A

Exchange: London Stock Exchange

Sell:

0.00

Buy:

0.00

Change: 23.19 ( 0.27 %)

Date:

09/05/2025 - 16:59

Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.